百奥泰(688177.SH)：2025年预亏2.8亿元至3.9亿元

Core Viewpoint - The company Baiotai (688177.SH) is expected to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a decrease in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is projected to be between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The company is actively expanding its market presence, with steady sales growth for its products, including Adalimumab Injection (Geleli®) and Tocilizumab Injection (Shiruili®) compared to the previous year [1] - The launch of Ustinumab Injection (STARJEMZA®) in the United States has contributed to increased licensing and sales revenue [1]